AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03949296 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Hygiene
Description: Session includes a handout with15 sleep hygiene tips:~1. Maintain a regular sleep pattern~2. Only try to sleep when feeling tired or sleepy~3. If unable to sleep, do something calm until feeling tired and returning to bed~4. Avoid caffeine \& nicotine for 4-6 hours before going to bed~5. Avoid alcohol for 4-6 hours before going to bed~6. Use the bed only for sleeping and sex~7. Avoid naps during the day~8. Develop rituals to get relaxed and ready to sleep~9. Try a hot bath prior to bedtime~10. Avoid checking the clock during the night~11. Use a sleep diary for a few weeks to track progress~12. Avoid strenuous exercise before bedtime~13. Avoid a heavy meal before bedtime~14. Create a sleep environment that is quiet, comfortable, and dark~15. Maintain a regular daytime routine
Study NCT02853643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002
Description: Single dose study with food effect
Study NCT02393144 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transperineal ultrasonography, General Electric Healthcare Voluson Ultrasound System
Description: Assessment of cervical dilatation, angle of progression and head position via transperineal ultrasonography
Study NCT02393144 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiotocography, Bionet FC1400 Fetal Monitor
Description: Assessment of strength of uterine contractions (Montevideo units) and fetal heart rate (beat per minute) with electronic monitors.
Study NCT02393144 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Amniotomy
Description: Artificial rupture of membranes to assess meconium staining and induce labor speed.
Study NCT02393144 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Analgesics, Opioid, Meperidine
Description: Administration of meperidine for labor analgesia.
Study NCT00337194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Given IV
Study NCT04751175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: A meta-analysis published in September 2011 affirms that the administration of dexamethasone at a dose of 0.1 mg / kg is an effective complement to multimodal analgesia strategies to reduce postoperative pain and opioid consumption after surgery.~Preoperative administration of the drug produces a more consistent analgesic effect than intraoperative administration
Study NCT04751175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: A meta-analysis published in September 2011 affirms that the administration of dexamethasone at a dose of 0.1 mg / kg is an effective complement to multimodal analgesia strategies to reduce postoperative pain and opioid consumption after surgery.~Preoperative administration of the drug produces a more consistent analgesic effect than intraoperative administration
Study NCT00337194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00337194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00337194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00337194 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00337194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00337194 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study NCT02783989 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: white wine
Description: A dietary beverage: a market white wine, 13º alcohol
Study NCT02783989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: white wine
Description: A dietary beverage: a market white wine, 13º alcohol
Study NCT02783989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tyrosol
Description: tyrosol in capsules
Study NCT00004032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-hB7.1
Description: Given IP
Study NCT00004032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon gamma
Description: Given IP
Study NCT00004032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02476682 — intervention group
Intervention type: OTHER
Intervention: blood or stool samples will be collected
Description: blood or stool samples will be collected
Study NCT04453007 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-checkup to go
Description: The e-checkup to go alcohol program is designed to motivate individuals to reduce their alcohol consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
Study NCT04453007 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: e-checkup to go
Description: The e-checkup to go alcohol program is designed to motivate individuals to reduce their alcohol consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
Study NCT04453007 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feedback booster
Description: Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm.
Study NCT02822287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcystine
Description: Clear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle.
Study NCT03116087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone patch
Description: 300 mcg testosterone patches or placebo applied twice weekly
Study NCT03116087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patch
Study NCT04590183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK-506 (Drug)
Description: Twice a day
Study NCT04590183 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Prednisolone Acetate 1% Oph Susp
Description: Four times a day
Study NCT03675555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Each patient received 30 mg Mirta tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline \[NS\]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
Study NCT03675555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate
Description: Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
Study NCT03675555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 h preoperatively.preoperatively.
Study NCT01539889 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 99mTC-PulmoBind
Description: DFH-12 (PulmoBind) is a peptide derived from human adrenomedullin (hAMI-52). Adrenomedullin (AM) is a 52-amino acid peptide produced by many tissues in the body, including the vascular endothelium. 3 radiolabeled doses of PulmoBind will be used in this study (5mCi, 10mCi and 15mCi) 5 healthy subjects per dose for the 5 mci and the 10 mci groups but 10 subjects will be used for the 15 mci group.
Study NCT03276481 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral microbiota assessment
Description: Whole mouth microbiota will be assessed by having participants swish in their mouth 10 ml of sterile water for 30 sec and then expectorate in a sterile container. Specimens will be immediately placed on wet ice and transferred to the laboratory for processing or for storage at -80° C until they are ready to be prepared for sequencing.
Study NCT04751175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physiologic saline
Description: placebo
Study NCT03276481 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive chemical gustometry
Description: Chemical gustometry assessments will be performed by a trained clinician on the study team, including a Registered Dietitian, Physician's Assistant, or Research Nurse. The test solutions and gradients will be formulated in house using sterile water and the following constituents: Sweet taste; 0.05, 0.1, and 0.2 g/ml sucrose, sour taste; 0.05, 0.09, and 0.165 g/ml citric acid, salty taste; 0.016, 0.04, and 0.1 g/ml NaCl and bitter taste; 0.0004, 0.0009, and 0.0024g/ml quinine-HCl. Umami will be tested with MSG at 25, 50, and 75 mM.
Study NCT03276481 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of salivary flow
Description: Both stimulated and un-stimulated salivation will be assessed by saliva collection in pre-weighed plastic containers. Participants will be seated with their back at a 90 degree angle and asked to swallow everything in their mouth. They will then be asked not to swallow and spit the accumulated saliva in the plastic container every 30 seconds for two minutes (unstimulated flow). For measurement of stimulated saliva, we will follow the same procedure except that after the initial swallow, participants will have their tongue swabbed twice with a cotton swab dipped in ascorbic acid solution or lemon juice.
Study NCT03276481 — intervention group
Intervention type: BEHAVIORAL
Intervention: Surveys assessing taste disturbances
Description: Surveys will be administered and examine taste disturbances pre and post HCT.
Study NCT00635583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increased Dairy Consumption
Description: 3 additional servings of dairy (two of which must be milk or yogurt)~* 8 oz milk~* 6 oz yogurt~* 1.5 oz cheese
Study NCT02468375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron 50mg
Description: 434 OAB patient intake mirabegron 50mg/day for 12 weeks.
Study NCT04633720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changes in positive end-expiratory pressure and tidal volume
Description: When the patient is in the supine position 10 minutes after induction of anesthesia, the following 4 mechanical ventilator settings are applied to the patients in order.~Positive end-expiratory pressure 8 cmH2O, tidal volume 8 ml/kg Positive end-expiratory pressure 10 cmH2O, tidal volume 5 ml/kg Positive end-expiratory pressure 10 cmH2O, tidal volume 8 ml/kg Positive end-expiratory pressure 12 cmH2O, tidal volume 5 ml/kg
Study NCT01132690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa
Description: Taliglucerase alfa for infusion every two weeks for 12 months
Study NCT03322891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Supplement
Description: Participants will receive education about prostate cancer and treatments using models and props during a face-to-face interview. During the interview, participants will also be asked about medical terms and treatments regarding prostate cancer. The interview will last 45 to 60 minutes.
Study NCT03322891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Practice Education
Description: Participants will receive traditional standard of care education regarding prostate cancer treatments and side effects provided by their physician.
Study NCT05446155 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: Diagnostic and prognostic imaging, omics and machine learning methods will be applied
Study NCT02334254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban and ticagrel therapy
Description: Antiplatelet therapy are mandatory at least 1 month after bare metal stent implantation, and 6 months after drug-eluting stent implantation.
Study NCT02334254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triple antithrombotic regimen with warfarin, asipirin and clopidogrel
Study NCT00944021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 50mg
Study NCT00944021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 100mg
Study NCT00944021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 150 mg
Study NCT00944021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifafour e-275 mg
Description: 275 mg
Study NCT00944021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 200 mg
Study NCT05099588 — intervention group
Intervention type: OTHER
Intervention: Other: observational study
Description: Observational study
Study NCT05986058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Golden Circle
Description: The original Golden Circle project was deployed in response to the COVID-19 pandemic and the need to implement remote social services in South Korea. Golden Circle had the aim of building a case management model using a healthcare-oriented automation system based on wearable devices (smartwatches and mobile applications). Through innovative system expansions, the goals were to promote healthful CVH and physical function and cultivate self-care management skills in older Korean adults.
Study NCT04751175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physiologic saline
Description: placebo
Study NCT06354842 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: pilocarpine iontopheresis
Description: Application of pilocarpine on the skin of the patients/subjects to induce sweat production to analyse sweat sodium concentration via flame photometry
Study NCT02393144 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Labor augmentation, Oxytocin
Description: Oxytocin infusion for augmentation of labor.
Study NCT02393144 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Labor induction, Oxytocin
Description: Oxytocin infusion for induction of labor.
Study NCT02393144 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cervical ripening, labor induction, Dinoprostone
Description: Administration of dinoprostone pessary for cervical ripening and labor induction.
Study NCT03186651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TVS
Description: Efficacy of a novel intra-vaginal device for temporary reduction of urine leakage in women suffering from stress urinary incontinence and to evaluate the safety and ease of use.
Study NCT01923909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-articular platelet-rich plasma
Description: Intra-articular platelet-rich plasma This involves withdrawal of 10-15cc of patient's blood, which is collected and centrifuged in Rotofix 32 A Centrifuge machine at 1500 cycles/minute for 5 minutes. 3-4cc of the PRP is obtained and injected into the supra patellar pouch using an aseptic technique. The procedure will be performed by the principal investigator, a qualified consultant Orthopedic surgeon. Analgesia will be administered as needed.
Study NCT01923909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular corticosteroid injections
Description: Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the supra patellar pouch. After an IA corticosteroid injection, patients are always advised to rest for 24 hours, and weigh bear as little as possible for the following 3 days. The procedure will be performed by a senior resident with several years of experience or a consultant Orthopedic surgeon.
Study NCT03287154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS stimulations
Description: 20 min, 2mA
Study NCT03287154 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: 20 min, Sham
Study NCT03720444 — intervention group
Intervention type: OTHER
Intervention: MDT (mechanical diagnosis and therapy) method
Description: The intervention consists of a first session to carry out an assessment, followed by 4 reassessment sessions
Study NCT04363359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5ml Quadrivalent influenza vaccine
Description: The inactivated split virion vaccines contained 15 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2, B/Victoria and B/Yamagata strains
Study NCT04363359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.25ml Quadrivalent influenza vaccine
Description: The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2, B/Victoria and B/Yamagata strains
Study NCT04363359 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0.25ml Trivalent influenza vaccine(B/V)
Description: The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2 and B/Victoria strains
Study NCT04363359 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0.25ml Trivalent influenza vaccine(B/Y)
Description: The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2 and B/Yamagata strains
Study NCT03886129 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Doppler Ultrasound (TCD)
Description: Participants will undergo an assessment of brain blood flow using TCD, with two small ultrasound probes held in place on the temples with a customised headframe. During the assessment, heart rate, breathing and blood pressure will also be monitored using a 3 lead ECG, nasal capnography and Finometer® respectively. The assessment will comprise three recordings. Firstly, participants will sit quietly for 5 minutes. Next, they will be asked to sit quietly for one minute before standing and remaining standing for 5 minutes. Lastly, they will be asked to stand and then complete a squat-stand manoeuvre in time with a computer sequence. A tilt sensor attached to the thigh will measure the efficiency and angle of the squatting motion. The squat-stand manoeuvre will consist of 15 squats and participants will be informed that they should try and complete all 15 squats if possible.
Study NCT04751175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline
Description: placebo
Study NCT00231894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: pioglitazone 30-45 mg/day
Study NCT00231894 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life style diet group
Description: life style diet education group 1x/week
Study NCT00231894 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Life style diet group
Description: life style diet education group 1x/week
Study NCT00231894 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator capsules
Study NCT01236027 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: not applicable-no intervention
Study NCT04181541 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Provider type: Physicians
Description: In this cohort, women will receive second trimester medical abortion care from physicians
Study NCT04181541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Provider type: Midlevel Providers
Description: In this cohort, women will receive second trimester medical abortion care from midlevel providers.
Study NCT04110873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antroquinonol Capsule 50mg
Description: patients will receive Antroquinonol 50mg per day (QD) on Day 1 for 12 weeks
Study NCT04110873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antroquinonol Capsule 100mg
Description: patients will receive Antroquinonol 100mg per day (QD) on Day 1 for 12 weeks
Study NCT04110873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: patients will receive placebo per day (QD) on Day 1 for 12 weeks
Study NCT05181943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simpler diode laser
Description: Non-contacting irradiation for 30 seconds on three intraoral sites repeated four times
Study NCT05181943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional symptomatic treatment
Description: Conventional treatment using oracure, BBC spray, miconaz three times daily
Study NCT01471067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m2 by vein on Day -2 only for Fludarabine + Melphalan group.
Study NCT01125072 — intervention group
Intervention type: OTHER
Intervention: Echocardiography with strain analysis
Description: Clinical routine echocardiogram with additional off line strain analysis